Inventor · disambiguated record
Chris Hidemi Mizufune Takimoto
Also filed as: TAKIMOTO CHRIS H · TAKIMOTO CHRIS HIDEMI MIZUFUNE
5 granted patents·5 pending applications·16 citations·filing 2001–2023
72Inventor score
Top patents by PatentIndex Score
10 records- 0177US11891450B2Anti-CD47 agent-based treatment of CD20-positive cancerFORTY SEVEN INC·Filed 2019·Granted Feb 6, 2024·1 cites·20 claims
- 0275US7655694B2Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injuryUS HEALTH·Filed 2001·Granted Feb 2, 2010·14 cites·30 claims
- 0373US2024218077A1Anti-cd47 agent-based treatment of cd20-positive cancerFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 0472US2024150461A1Anti-cd47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 0567US2024124578A1Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemiaFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 0663US8349888B2Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injuryUS HEALTH·Filed 2010·Granted Jan 8, 2013·1 cites·20 claims
- 0762US11802153B2Anti-CD47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2018·Granted Oct 31, 2023·0 cites·17 claims
- 0860US11795223B2Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemiaFORTY SEVEN INC·Filed 2020·Granted Oct 24, 2023·0 cites·12 claims
- 0950US2021147568A1Anti-cd47 based treatment of blood cancerFORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 1044US2021047416A1Treatment of ovarian cancer with anti-cd47 and anti-pd-l1FORTY SEVEN INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chris Hidemi Mizufune Takimoto files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →